Zynerba Pharmaceuticals (NASDAQ: ZYNE) stock is up some 300%. ZYNE stock is up because Harmony is offering to buy the whole company. Which is very nice indeed for those holding a position in Zynerba before this. However, the current market price is well above the cash price on offer - so what’s happening here? The answer being that there are also some contingents on offer. Not unusual in the takeover of development pharma companies contingents are the ability of the selling shareholders to still partake in the success of the drugs if they do eventually gain approval and marketing. It’s like a special class of stock linked tightly to the performance of the company being taken over that is.
The deal itself: “Per the terms, Harmony (HRMY) is expected to start a tender offer to acquire all outstanding shares of Zynerba for $1.1059 per share or $60M in cash.
Zynerba (ZYNE) investors will also receive one non-tradeable contingent value right (CVR) valued at up to about $2.5444 per share, or $140M in additional cash payments in total, subject to the achievement of certain clinical, regulatory, and sales milestones.” And that, of course, is where the contingents come in.
Zynerba Pharmaceuticals stock price from Google Finance
If the cash price on offer is $1.10 and the market price is $1.35 then clearly those contingents are currently valued at $0.25 each. Given that the payout is capped at about ten times that this may or may not be a reasonable valuation - that will be a matter of opinion of course.
There is, however, something that does occasionally happen in such circumstances. This idea of contingents is common enough in such development pharma takeovers. But sometimes the market just seems to decide that it would like the cash now, thank you very much. It has been true that we’ve seen contingents thus valued at or near nothing. And while 25 cents might be over what we think those contingents in Zynerba are worth - or below of course - that calculation changes if they’re priced at 10 cents, or 1 cent.
Thus our recommendation here. Monitor that Zynerba price. If it falls back to $1.10, or even better below it, then it could well be worth picking som up. At the price of the dealing costs those contingents could be picked up for near or at nothing. They’re not tradeable, they’ll not be quoted or listed, but something near free that just sits at the back of the portfolio and we wait and see - well, why not?
Note that we do not say that the price will fall back - this is itself contingent. If it does then those contingent rights fall in price and at some price they’re worth having.